Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

B-cell Lymphoma Refractory Clinical Trial

Official title:

A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-AIO, a Triple-targeted Cell Preparation Targeting CD19/CD20/CD22, in Patients With Relapsed/Refractory B-cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05318963
• Other study ID #: BM2L202102
• Status: Recruiting
• Phase: Phase 1
• Start date: March 14, 2022
• Est. completion date: June 30, 2026

Study information

• Verified date: August 2023
• Source: Institute of Hematology & Blood Diseases Hospital
• Contact: Wei Liu
• Phone: 86-022-23909282
• Email: liuwei[@]ihcams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LCAR-AIO, a triple-targeted cell preparation targeting CD19/CD20/CD22, in patients with relapsed/refractory B-cell lymphoma.

Description:

This is an open-label, dose-escalation/dose extension study to assess the safety, tolerability, and efficacy of LCAR-AIO in the patient ≥ 18 years of age with relapsed or refractory B cell lymphoma. Subjects who meet the eligibility criteria will receive a single dose of LCAR-AIO injection. The study will include the following sequential phases: screening, pre-treatment (cell product preparation; lymphodepleting chemotherapy), treatment, and follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 34
• Est. completion date: June 30, 2026
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent.

2. Aged 18-75 years (inclusive).

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

4. Histologically confirmed B-cell lymphoma that expresses at least one of CD19/CD20/CD22.

5. At least one measurable tumor lesion determined according to Lugano 2014 criteria.

6. Response to prior therapy is consistent with one of the following:

1. Primary refractory: it means that the best response to first-line therapy (at least 2 cycles) is PD, or best response to first-line therapy (at least 4 cycles) is SD but the duration is less than 6 months, which is considered to be PD;

2. Relapsed or refractory after 2 or more lines of therapy. Refractory is defined that best respond to the most recent treatment regimen (at least 2 cycles) is PD, or best response to the most recent treatment regimen (at least 4 cycles) is SD but the duration is less than 6 months, which is considered to be PD;

3. Progression or relapse within 12 months after hematopoietic stem cell transplantation; if salvage therapy is applied after transplantation, the patient must be unresponsive or relapsed to the last line of therapy;

7. Life expectancy= 3 months

8. Clinical laboratory values meet screening visit criteria

9. Adequate organ function;

Exclusion Criteria:

Subject eligible for this study must not meet any of the following criteria:

1. Prior antitumor therapy with insufficient washout period ;

2. Patients who received dual-targeted CAR-T cell therapy (including but not limited to sequential infusion) at any time in the past, or who received CAR-T cell therapy of cameloid origin;

3. With acute or chronic graft-versus-host disease (GvHD);

4. Patients who are positive for any index of hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), or human immunodeficiency virus antibody (HIV- Ab).

5. Known life-threatening allergies, hypersensitivity, or intolerance to LCAR-AIO CAR-T cell or its excipients, including DMSO (refer to Investigator's Brochure).

6. Pregnant or lactating women;

Related Conditions & MeSH terms

• B-cell Lymphoma Recurrent
• B-cell Lymphoma Refractory
• Lymphoma
• Lymphoma, B-Cell

Intervention

Biological:
• LCAR-AIO cells product
before treatment with LCAR-AIO cells, subjects will receive a conditioning regimen (IV infusion of cyclophosphamide 300 mg/m^2 and fludarabine 30mg/m^2 once daily (QD) for 3 days.

Locations

Country	Name	City	State
China	Beijing Gobroad Boren Hospital	Beijing	Beijing
China	Institute of Hematology & Blood Diseases Hospital	Tianjin	Tianjin

Sponsors (2)

Lead Sponsor	Collaborator
Qiu Lugui	Nanjing Legend Biotech Co.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence, severity and type of TEAEs (Treatment-emergent Adverse Events)	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.	Minimum 2 years after LCAR-AIO infusion (Day 1)
Primary	Pharmacokinetics in peripheral blood	CAR positive T cells and CAR transgene levels in peripheral blood after LCAR-AIO infusion.	Minimum 2 years after LCAR-AIO infusion (Day 1)
Primary	Pharmacokinetics in bone marrow	CAR positive T cells and CAR transgene levels in bone marrow after LCAR-AIO infusion.	Minimum 2 years after LCAR-AIO infusion (Day 1)
Primary	The recommended Phase II dose (RP2D) for this cell therapy	RP2D established through ATD+BOIN design and the DLTs occurring following CAR T-cell infusion	30 days after LCAR-AIO infusion
Secondary	Overall Response Rate (ORR)	Objective Response Rate (ORR) is defined as the proportion of subjects who achieve CR or PR after treatment via LCAR-AIO cell infusion	Through study completion, minimum 2 years after LCAR-AIO infusion (Day 1)
Secondary	Progression-free survival (PFS)	Progression Free Survival (PFS) is defined as the time from the date of first infusion of the LCAR-AIO to the first documented disease progression (according to Lugano 2014) or death (due to any cause), whichever occurs first	Through study completion, minimum 2 years after LCAR-AIO infusion (Day 1)
Secondary	Overall Survival (OS)	Overall Survival (OS) is defined as the time from the date of first infusion of LCAR-AIO to death of the subject	Through study completion, minimum 2 years after LCAR-AIO infusion (Day 1)
Secondary	Time to Response (TTR)	Time to Response (TTR) is defined as the time from the date of first infusion of LCAR-AIO to the date of the first response evaluation of the subject who has met all criteria for CR or PR.	Through study completion, minimum 2 years after LCAR-AIO infusion (Day 1)
Secondary	Duration of Response (DoR)	Duration of Remission (DoR) is defined as the time from the first documentation of remission (CR or PR) to the first documented relapse evidence of the responders	Through study completion, minimum 2 years after LCAR-AIO infusion (Day 1)
Secondary	Immunogenicity assessment of LCAR-AIO cells	The incidence of Anti-LCAR-AIO antibody in patients who received LCAR-AIO cells infusion	Through study completion, minimum 2 years after LCAR-AIO infusion (Day 1)